Booting Earth Optimization System
Thank you for your patience. Your civilization is very important to us.
Thank you for your patience. Your civilization is very important to us.
“Real-time Outcome Labels & Treatment Rankings”
— Wishonia, Planetary Systems Engineer
Not graded: only two sourced estimates of drug development cost exist. FDA's total program level rose 466% (FY2000 $1.21B → FY2024 $6.88B, nominal). Tufts CSDD's estimated cost per approved drug rose 145% after inflation — $1.04B to $2.56B in 2013 dollars — between drugs first tested in 1983–94 and 1995–2007.
“The FDA's budget grew more than fivefold and the cost of developing a drug more than doubled after inflation. That is not regulation. That is a protection racket with a government seal.”
— Wishonia
8.2 years from safety proof to patient access. The delay IS the business model — it protects pharma exclusivity, not patients.
Approving a drug that harms 100 = career over. Blocking a drug that could save 100,000 = nobody notices. The FDA optimizes for the first.
75% of drug review costs are paid by the companies being reviewed. The regulator is funded by the regulated.
Zero. If it's proven safe, patients can access it immediately.
Every treatment gets a continuously-updated label showing effectiveness, side effects, and optimal dosage from real-world data.
For any condition, see all treatments ranked by effectiveness, safety, and confidence — updated in real-time.
Protect public health by ensuring safety and efficacy of drugs and food
2003 Medicare Part D signed — pharma lobbies a BAN on government negotiating drug prices ↗
2004 Vioxx withdrawn — FDA knew about cardiac risks for years, approved anyway ↗
2024 Same drug: Insulin US $300, Canada $30. Humira US $80K, UK $15K. ↗
Not graded: only two sourced estimates of drug development cost exist. FDA's total program level rose 466% (FY2000 $1.21B → FY2024 $6.88B, nominal). Tufts CSDD's estimated cost per approved drug rose 145% after inflation — $1.04B to $2.56B in 2013 dollars — between drugs first tested in 1983–94 and 1995–2007.
| Year | FDA total program level: budget authority + user fees (nominal USD, fiscal year; excludes COVID supplementals) | Tufts CSDD estimated R&D cost per approved new drug (USD millions, 2013 dollars; plotted at study publication year) |
|---|---|---|
| 2000 | $1.21B | – |
| 2003 | – | 1,044 |
| 2004 | $1.68B | – |
| 2008 | $2.42B | – |
| 2010 | $3.28B | – |
| 2012 | $3.83B | – |
| 2014 | $4.39B | 2,558 |
| 2016 | $4.75B | – |
| 2018 | $5.27B | – |
| 2020 | $5.92B | – |
| 2022 | $6.25B | – |
| 2024 | $6.88B | – |
Average delay from safety proof to FDA approval
Estimated deaths waiting for treatments already proven safe
Average cost to bring one drug to market through the FDA process
8.2-year queue → real-time outcome data
// The dFDA replaces the approval queue with continuous evidence:
// Stage 1: Real-world evidence from existing data ($1/patient)
// Stage 2: Pragmatic trials in routine care ($929/patient)
// Every treatment gets an Outcome Label — updated in real-time
// See: dfda.earth for the full specificationInstead of a binary approve/reject gate, treatments get continuously-updated Outcome Labels showing what actually happens when real humans take them. Doctors and patients see effectiveness, side effects, and confidence levels — from millions of data points, not a single trial of 200 people.
The value is measured in lives, not dollars. 102 million people died waiting for treatments that were already proven safe.
“Your FDA has two speeds: 'not yet' and 'too late.' The queue exists because a bureaucrat who approves a drug that hurts 100 people gets fired, but a bureaucrat who blocks a drug that could save 100,000 gets promoted. The incentives are perfect — for killing people slowly.”
— Wishonia
Every Earth agency has a simpler replacement. Fund the campaign, see the system, set your priorities.